ReviewNature reviews. Immunology2022
Heterogeneity of type 2 innate lymphoid cells.
Review in Nature reviews. Immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 1 synthesis or guideline pooled it, 137 citations in OpenAlex.
- Immune and inflammatory mechanisms in asthma: insights into epigenetic modifications.Frontiers in immunology · 2025Pooled it
- Rapid and Highly Efficient CRISPR-Cas9 RNP Genome Editing in Primary ILC2s.European journal of immunology · 2026Article
- Interleukin-4-producing type 2 innate lymphoid cells in the lymph node promote proallergic Tfh13 cell differentiation.Immunity · 2026Article
- Group 2 innate lymphoid cells: Where are we 15 years out?The Journal of allergy and clinical immunology · 2026Review
- MyD88 mediates allergic airway inflammation by regulating ILC2s function through inducing the formation of P38/GATA3 complex.Respiratory research · 2026Article
- ILC2s and their immune checkpoints in the antitumor response.Journal for immunotherapy of cancer · 2026Review
- IL-33 promotes transcriptional and metabolic adaptations of tissue-resident Th2 cells.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- GPX4-dependent ferroptosis governs ILC2 homeostasis and colitis progression.Cellular & molecular immunology · 2026Article
- Tumor-infiltrating immature innate lymphoid cells in colorectal cancer are biased toward ILC1/tissue-resident NK cell differentiation.Nature communications · 2026Article
- Involvement of increased arginase-1The Journal of international medical research · 2026Article
- Mast-cell derived nerve growth factor drives ILC2 pro-tumoral functions in bladder cancer.Nature communications · 2026Article
- Innate lymphoid cell heterogeneity and etiology-specific reprogramming in hepatocellular carcinoma.NPJ precision oncology · 2026Article
- Human type-1 innate lymphoid cells control leukemia stem cell differentiation and limit acute myeloid leukemia development.Nature communications · 2026Article
- Innovative approaches targeting innate immune cells to promote organ transplant tolerance.Frontiers in transplantation · 2026Review
- Identification, characterization, and expansion of innate lymphoid cells derived from canine peripheral blood mononuclear cells.Frontiers in immunology · 2026Article
- Development and computational analysis of high dimensional spectral flow cytometry data for the resolution of innate lymphoid cells in the mammary tumor microenvironment.Frontiers in immunology · 2026Article
- RAG1 deficiency durably alters dermal group 2 innate lymphoid cells and modifies contact hypersensitivity.Frontiers in immunology · 2026Article
- Innate airway immune response to fungal allergens.Frontiers in immunology · 2026Review
- Construction of a Bioactive ECM Interface Enables Concurrent Suppression of Foreign Body Reaction, Inflammation, and Promotion of Urethral Regeneration.Biomaterials research · 2026Article
- Modulation of type 2 inflammation during grass pollen-specific sublingual immunotherapy.Frontiers in immunology · 2026Article
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
More than a decade ago, type 2 innate lymphoid cells (ILC2s) were discovered to be members of a family of innate immune cells consisting of five subsets that form a first line of defence against infections before the recruitment of adaptive immune cells. Initially, ILC2s were implicated in the early immune response to parasitic infections, but it is now clear that ILC2s are highly diverse and have crucial roles in the regulation of tissue homeostasis and repair. ILC2s can also regulate the functions of other type 2 immune cells, including T helper 2 cells, type 2 macrophages and eosinophils. Dysregulation of ILC2s contributes to type 2-mediated pathology in a wide variety of diseases, potentially making ILC2s attractive targets for therapeutic interventions. In this Review, we focus on the spectrum of ILC2 phenotypes that have been described across different tissues and disease states with an emphasis on human ILC2s. We discuss recent insights in ILC2 biology and suggest how this knowledge might be used for novel disease treatments and improved human health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.